No Detail Found!

Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1‑1639 genetic polymorphisms in Thai patients

Author(s)
Burassakorn Subsuphan Departments of Pharmacy, Phaholpolpayuhasena Hospital, Kanchanaburi, Thailand
Chatchai Chinpaisal Surgery, Phaholpolpayuhasena Hospital, Kanchanaburi Thailand
Manat Pongchaidecha Departments of Pharmacy, Faculty of Pharmacy, Silpakorn University, Sanam Chandra Palace Campus, Muang, Nakhon Pathom, Thailand
Wibun Phanthabordeekorn Departments of Pharmacy, Faculty of Pharmacy, Silpakorn University, Sanam Chandra Palace Campus, Muang, Nakhon Pathom, Thailand
Surawut Watana Surgery, Phaholpolpayuhasena Hospital, Kanchanaburi Thailand
Abstract
Aims: The purposes of this study were to investigate the influence of genetic polymorphisms of cytochrome P450 2C9 (CYP2C9)*3 and Vitamin K epoxide reductase complex subunit 11-639 (VKORC11-639) G >A and patient's characteristics on warfarin dose requirement and to establish an equation for predicting the warfarin maintenance dose in Thai patients. Settings and Design: This is an observational, retrospective study in outpatients. Ninety-one outpatients receiving warfarin at Phaholpolpayuhasena Hospital, Kanchanaburi, were recruited to this study. Subjects and Methods: Whole blood, dose, and demographic data were collected. Blood samples were analyzed for the genetic polymorphism by restriction fragment length polymorphism technique. Statistical Analysis Used: Differences in baseline characteristics among genotypes were evaluated by analysis of variance or Kruskal-Wallis and the Mann-Whitney U-test or Chi-square test for parametric and nonparametric variables, respectively. Association between genetic factors and warfarin dose was based on Eta test, whereas associations between warfarin dose and polymorphisms were evaluated using Pearson correlation test. Stepwise regression was used to identify factors contributing to warfarin dose requirement followed by linear regression model to develop a warfarin dosing algorithm. Results: CYP2C9*1*1 (wild type) genotype was found in 90 patients (98.90%), and CYP2C9*1*3 was found in only 1 patient (1.10%). No CYP2C9*3*3 genotype was observed. Polymorphisms of VKORC1-1639 GG was found in 9 patients (9.89%) while GA and AA genotype were found in 30 patients (32.97%) and in 52 patients (57.14%), respectively. Patients with VKORC1-1639 AA genotype required statistically and significantly lower, average weekly warfarin dose (19.97 ± 7.61 mg) than GG genotype (37.89 ± 12.20 mg) and GA genotype (29.48 ± 11.50 mg) with the P < 0.05. Conclusions: Using stepwise multiple linear regression, VKORC1-1639 AA, age, and weight could explain about 45.3% of the variation of warfarin maintenance dose. Multivariate analysis of the equation indicated a significant negative correlation between warfarin dose and VKORC1-1639 AA and age, but a significant positive correlationbetween warfarin dose and weight. This suggested that VKORC1 genotyping may be more important in warfarin dose adjustment and should be a priority for genotype measurement.
Publication Details
Page(s) 18-26
Published Journal: Archives of Pharmacy Practice, Volume: 7, Issue: 1, Year: 2016

Request the full text from PASTIC

Keywords
Warfarin, Vitamin K epoxide reductase complex subunit 1, Cytochrome P450 2C9 isozyme, genetic polymorphism
References
Oldenburg J,Watzka M,Rost S,Müller CR .2007 .Molecular target of coumarins. J Thromb Haemost, 5(Suppl 1) : 1-6.
Garcia AA,Reitsma PH .2008 .VKORC1 and the Vitamin K cycle. Vitam Horm, 78 : 23-33.
Jaruchotikamol A .2010 .Warfarin and genetic polymorphism. Thai Pharm Health Sci J, 5 : 180-4.
Schalekamp T .2010 .Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des, 16 : 1872-03.
Ozer N,Cam N,Tangurek B,Ozer S,Uyarel H,Oz D .2010 .The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessels, 25 : 155-62.
Wadelius M,Chen LY,Eriksson N,Bumpstead S,Ghori J,Wadelius C .2007 .Association of warfarin dose with genes involved in its action and metabolism. Hum Genet, 121 : 23-34.
Oldenburg J,Bevans CG,Fregin A,Geisen C,Müller‑Reible C,Watzka M. .2007 .Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost, 98 : 570-8.
Kudzi W,Dodoo AN,Mills JJ .2009 .Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet, 10 : 124.
Geisen C,Watzka M,Sittinger K,Steffens M,Daugela L,Seifried E .2005 .VKORC1 haplotypes and their impact on the inter‑individual and inter‑ethnical variability of oral anticoagulation. Thromb Haemost, 94 : 773-9.
Rieder MJ,Reiner AP,Gage BF,Nickerson DA,Eby CS,McLeod HL .2005 .Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 352 : 2285-93.
FDA. Silver US . .Spring (MD). Coumadin (Warfarin Sodium) Tablet and Injection. [Last cited on 2011 Jul, 05 : .
Sangviroon A,Panomvana D,Tassaneeyakul W,Namchaisiri J .2010 .Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. Drug Metab Pharmacokinet, 25 : 531-8.
Kuanprasert S,Dettrairat S,Palacajornsuk P,Kunachiwa W,Phrommintikul A .2009 .Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand. J Med Assoc Thai, 92 : 1597-601.
Klamchuen S,Chuansumrit A,Angchaisuksiri P,Sasanakul W. . .Frequency of Polymorphisms associated with. , : .
0

Citations

0

Downloads

10

Views